I’m pretty sure that the intention is to treat anyone with the condition, regardless of age.
Re market numbers, I have provided below the patient population numbers used by Neuren, who are also developing a drug (NNZ-2591) in this same condition.
1 Estimates derived by applying the mid-point of the prevalence estimate range to the populations under 60 years
2 Asia comprises Japan, Korea, Taiwan, Israel and urban populations of China and Russia
PYC Price at posting:
6.6¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)